NextCell approved for trading on Nasdaq First North

NextCell Pharma AB (publ) (“NextCell” or “the Company”) announces that Nasdaq Stockholm AB today has approved their application for trading on Nasdaq Stockholm First North. The last day for trading on Spotlight is Tuesday, July 21, 2020 and the first day for trading on Nasdaq First North is Wednesday, July 22, 2020.

The shares in NextCell will be traded with unchanged ticker (NXTCL) and ISIN code (SE0009723125) and shareholders in NextCell need not take any action in connection with the list change.

"The list change is a natural step in our development and is expected to attract a broader group of investors, as well as give the company better access to the Swedish and international capital markets," says Mathias Svahn, CEO.

A prospectus for NextCell is available on the company's website, www.nextcellpharma.com

FNCA Sweden AB is NextCells Certified Adviser on Nasdaq First North Stockholm.


Stay up to date with the latest development in NextCell Pharma

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

 

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Sofia Fredrikson, CFO

Phone: 08-735 5595

E-mail: info@nextcellpharma.com

 

Website:

www.nextcellpharma.com

www.cellaviva.se

www.cellaviva.dk

About NextCell Pharma AB:
NextCell is a Phase II cell therapy company with the lead candidate ProTrans™,  for the treatment of type-1 diabetes. Focus is to take ProTrans™  to market approval via a phase III study. Furthermore, NextCell operates Cellaviva, Scandinavia's largest stem cell bank for family-saving of stem cells from umbilical cord blood and umbilical cord tissue with permission from IVO.

Subscribe

Documents & Links